The vast majority of non-Hodgkin‘s lymphoma (NHL) are B-cell NHLs, the most common being diffuse large B-cell lymphoma (DLBCL). While most patients with DLBCL respond to initial therapy, over a third will develop refractory or relapsed (R/R) disease. Although there is no established standard of care, recent approvals of bispecific T-cell engagers, emerging therapies, and developing data are changing the treatment paradigm in R/R DLBCL. In this activity, Drs. Allison Rosenthal and Yasmin Karimi will review the latest conference data on current and emerging bispecific antibodies for R/R DLBCL.
Upon completion of this activity, participants should be better able to:
Assistant Professor, Medicine
University of Michigan
Ann Arbor, MI
Assistant Professor, Medicine
Medical Director, Adolescent and Young Adult Cancer Program
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Yasmin H. Karimi, MD, has relevant financial relationships with ADC Therapeutics SA (Advisor).
Allison C. Rosenthal, DO, has relevant financial relationships with Acerta Pharma, LLC, ADC Therapeutics SA, Celgene, Curis, Inc., GB005 Inc., Genmab US, Inc., Incyte Corporation, LOXO Oncology, Inc., Miltenyi Biotec, Novartis, Zhejiang DTRM Biopharma Co. Ltd. (Grants/Funded Research).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
There is no fee to participate.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources